Name
RF1-07: Multifactor analysis for pathologic complete response (pCR) in a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab (DTP Trial) in HER2-enriched early breast cancer.
Date & Time
Wednesday, December 11, 2024
Speakers
Virtual Session Link
Total Minutes
06:29
OnDemand Video URL